Linked Life Data

11498830

Source:http://linkedlifedata.com/resource/pubmed/id/11498830

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-8-10
pubmed:abstractText
Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality. The benefits extend to pre- and postmenopausal women and those with node-negative, node-positive, estrogen receptor (ER)-positive, and ER-negative disease. Updated data regarding chemoendocrine therapy in postmenopausal women and anthracycline-based regimens are presented. Dose intensity, dose density, and high-dose therapy have not been proven efficacious to date, but further trials are pending. The incorporation of taxanes and bisphosphonates has been further elucidated, with follow-up studies in progress. The potential role of trastuzumab is the focus of several clinical trials. Recent findings regarding the long-term side effects of adjuvant therapy are reviewed. These risks may outweigh the benefit derived from chemotherapy in a subset of patients who have excellent overall survival (OS) with small tumors, good prognostic features, or favorable histologic subtypes. This report will review the current state of adjuvant chemotherapy for early-stage breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
359-76
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Adjuvant chemotherapy for breast cancer: an update.
pubmed:affiliation
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA.
pubmed:publicationType
Journal Article, Review